As biosimilars begin to gain traction in the U.S. pharmaceutical market, the distinct labeling requirements applicable to them are likely to affect product liability litigation in this area, raising implications that are potentially distinct from those applicable to biologics and to small-molecule, generic drugs write Products Litigation and Counseling lawyers Glenn S. Kerner and IP Litigation lawyer and BMW editor, Alison Siedor. Read the For the Defense byline here.
The post Introduction To Biosimilars And Labeling Issues (For The Defense) appeared first on Big Molecule Watch.